Taysha Gene Therapies, Inc. (TSHA) Shareholders’ equity 2022–2025
Taysha Gene Therapies, Inc. (TSHA) shareholders’ equity at each fiscal year-end, per SEC filings.
$246.9MFY2025 · since FY2022: $949,000 → $246.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $246.9M | +245.2% |
| FY2024 | $71.5M | -4.6% |
| FY2023 | $74.9M | +7796.4% |
| FY2022 | $949,000 | — |
Source: SEC XBRL filings · For reference only · Not investment advice